Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
NAGE Stock Chart & Stats
$5.10
--
Market closed
$5.10
--
Day’s Range― - ―
52-Week Range$5.04 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)808.45K
Market Cap
$414.99M
Enterprise Value$345.93M
Total Cash (Recent Filing)$64.14M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)21.0
Beta0.93
Next Earnings
Mar 04, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding79,806,140
10 Day Avg. Volume925,085
30 Day Avg. Volume808,449
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.84
Price to Sales (P/S)4.55
P/FCF Ratio37.97
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.77
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda16.36
Forecast
1Y Price Target
$18.50Price Target Upside262.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyAcquisition of additional nicotinamide riboside patents strengthens TruNiagen's intellectual property, helping protect the brand from competitors and supporting potential pricing power.
Market DemandGrowing consumer interest in healthy aging and internal beauty can increase demand for proprietary NR products and support revenue growth per customer.
Product ExpansionLaunch of Tru Niagen Beauty in the US extends the franchise into internal beauty, enabling entry into new retail and direct-to-consumer channels and broadening the company's addressable market.
Bears Say
Clinical EvidenceA clinical study failed to show statistically significant improvement for long COVID symptoms with Niagen supplements, leaving efficacy in that patient segment unproven.
Commercial AdoptionUnproven benefits for long COVID could dampen uptake among patients and clinicians, reducing potential sales growth in that specific market opportunity.
Regulatory RiskInconclusive clinical results may limit ability to make therapeutic claims and invite regulatory scrutiny, constraining marketing into medical problem areas such as long COVID.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was $5.04 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is $414.99M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s upcoming earnings report date is Mar 04, 2026 which is in 21 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.018 by $0.032.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 79,806,140 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of $0.05 in its last earnings report, beating expectations of $0.018. Following the earnings report the stock price went down -1.007%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Currently, no hedge funds are holding shares in NAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (262.75% Upside)
$18.50 (262.75% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 101.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $45.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.60%
12-Months-Change
Fundamentals
Return on Equity
38.90%
Trailing 12-Months
Asset Growth
73.63%
Trailing 12-Months
Company Description
Niagen Bioscience
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
NAGE Company Deck
NAGE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with record revenue growth and strategic expansions. However, challenges remain in regulatory environments and pricing strategies in certain markets.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$18.50
▲(262.75% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
4.99% Insiders
9.16% Mutual Funds
0.37% Other Institutional Investors
78.28% Public Companies and Individual Investors
Options Prices
Currently, No data available
---